NYSE:PFE

Pfizer Inc (PFE)

25.01
+0.10 (0.40%)
as of Jul 31, 2026, 8:00:00 pm Market Open.
581 watching
0
Investor Insights
star iconAug 2, 2026, 12:00 am

This summary was created by AI, based on 23 opinions in the last 12 months.

Pfizer Inc. (PFE) is currently facing challenges following its pandemic-driven peak during which it surged due to COVID-19 vaccine sales. Experts have pointed out a lack of earnings momentum and concerns over a patent cliff, as key drugs have come off patent and the company needs to innovate to develop new blockbuster drugs. Despite these challenges, many analysts emphasize the attractive dividend yield, which remains around 6-8%. The company is pivoting towards growth areas such as obesity and oncology, and while there's a general belief that PFE is under pressure, patience from investors could yield positive results. Several insights indicate that while it may not attract immediate growth, the company’s efforts in acquisitions and drug development could eventually pay off, given time.

consensus icon
Consensus
Hold
valuation icon
Valuation
Undervalued
review icon
Similar
MRK
PAST TOP PICK
(A Top Pick May 30/23, Down 20%)

Strong dividend yield. Will continue to own shares. Weakness after the Covid-19 expected, but large decrease a surprise. However, strong pipeline of new drugs, and well known brand name. Expecting stock price to appreciate in the future. 

DON'T BUY
For the dividend and its push into oncology?

Look at the 30-year chart. Stock's around the same price today as then, despite the 10s of billions in acquisitions over the years. Partly speaks to industry conditions, partly to lack of blockbuster drugs. Dividend secure. Terrible investment for decades. Yield is 6%.

BUY

Pays a 6% dividend, which is good as rates fall. The PE is low, because they don't a lot of high-quality drug prospects now, but they bought Seagen which he really likes.

HOLD

At a pivotal point on the technical charts. Based down early this month and just moved up to 200-day MA, which is falling. If it can break that, it's positive for the stock. Really great dividend of 5.76% is fairly safe. If you're patient, it's OK. Stronger growth companies in healthcare, such as weight loss and diabetes. 8% growth rate.

DON'T BUY
Retired, looking for some growth and yield.

US dividend stocks don't usually pay nearly as much as Canadian ones. If he's looking for income, there are tax and other advantages to owning Canadian dividend stocks, especially in non-registered portfolios. 

Underperformer in the sector. Not in a growth area, which is weight loss right now. So he'd probably look at LLY and NVO. Those pipelines are probably going to be fairly robust.

TOP PICK

Ex-Covid, this is one of the biggest pharmas in the world that generates huge cash flow that supports a 6% dividend. He targets mid-$40s.

(Analysts’ price target is $32.10)
COMMENT

Selloff due to less demand from post Covid-19 selling. Believes was overvalued during. However, right now - could be a good time to buy. Expecting share price to recover to $40-$45. Would hold - good for long term investors. Owns in portfolio. 

BUY

Great company, that has turned the corner. Solid dividend with lots of cash on the balance sheet. 

DON'T BUY

It hasn't done much since the 1990's except during Covid. It's surprising that it is hiring a chief strategy and innovation officer that has been down on the stock for a decade, except for the oncology component.

BUY

Believes stock is bottoming out right now. New products are going to present opportunity. ~5.5% also good. 

BUY
They reported beats and raised forecast

They pay over a 6% dividend and trades at 9x PE. A wonderful story here. Will grow at a realistic 3-8% as you collect that dividend.

TOP PICK

It is down 60% from its peak and trading at 10X forward earnings with a 6% dividend yield, It took the windfall cash from the Covid vaccines, etc. and re-invested in new growth areas such as cancer, diabetic and weight loss treatments/ drugs., It is out of favour and there is potential for growth.
Buy 11  Hold 15  Sell 0

(Analysts’ price target is $31.76)
COMMENT

It reports Wednesday. He wants to hear how their purchase of Seagan has impacted the numbers.

DON'T BUY

No, though it might bounce and you can collect their dividend.

HOLD

Industry, overall, is fairly mature. Challenging to get drugs approved. Pharma companies are struggling to grow, dealing with patent cliffs. Flipside is generating good cashflows. Very attractive for income, but don't own it for share price performance, since growth is challenged. Yield is 6.5%, safe.

Showing 61 to 75 of 885 entries